Owens & Minor Inc/va/ 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Accendra Health, Inc. has implemented a Section 382 Rights Agreement to safeguard its net operating losses and other tax attributes, aiming to prevent an ownership change that could limit their utilization.
Accendra Health announced second quarter 2026 financial results, reporting a decrease in net revenue and an increase in net loss, alongside the news of CEO Edward Pesicka's planned retirement by year-end.
Accendra Health, Inc. announced that President and CEO Edward A. Pesicka plans to retire by the end of 2026, initiating a board-led search for his successor.
Accendra Health successfully finalized its debt exchange and consent solicitation, securing $326.25 million in new capital.
Accendra Health announced early results for its exchange offers, successfully tendering nearly all outstanding 2029 and 2030 notes, and issued new senior secured first and second lien notes.
Accendra Health has initiated exchange offers and consent solicitations for its 2029 and 2030 senior notes alongside a $326.25 million new money financing.
Accendra Health, Inc. announced shareholder approval of an Amended and Restated 2023 Omnibus Incentive Plan and the election of six directors at its 2026 Annual Meeting.
Accendra Health, Inc. announces a comprehensive transaction to refinance its debt, including new senior secured notes and a revolving credit facility, aiming to extend maturity profiles and improve financial flexibility.
Accendra Health reported Q1 2026 results aligned with expectations and announced a significant balance sheet optimization transaction exceeding $1.5 billion.
Accendra Health, Inc. announced its fourth quarter and full-year 2025 financial results, highlighted by the completion of its Products & Healthcare Services business sale and a strategic pivot towards its continuing operations.
Accendra Health, Inc. completed the sale of its Products & Healthcare Services business for $375 million and amended its receivables program, using proceeds to repay $280 million in long-term debt.
Owens & Minor, Inc. has completed the sale of its Products & Healthcare Services segment for $375 million and rebranded as Accendra Health, Inc., focusing on home-based care.
Owens & Minor, Inc. announced a corporate name change to Accendra Health, Inc. and a new NYSE ticker symbol ACH, alongside freezing its Executive Deferred Compensation and Retirement Plan.
Owens & Minor announced the appointment of Perry A. Bernocchi as Chief Operating Officer and the departure of its Chief Human Resources Officer, with HR oversight shifting to the General Counsel.
Owens & Minor announced management will present at investor conferences, detailing its strategic pivot to a pure-play home-based care business following the P&HS segment sale.
Owens & Minor reported Q3 2025 financial results, including significant net losses, while reaffirming its strategic pivot to a pure-play home-based care business.
Owens & Minor announced a definitive agreement to sell its Products & Healthcare Services segment to Platinum Equity for $375 million in cash, plus a 5% retained equity stake and over $150 million in tax attributes, as it shifts focus to home-based care.
Owens & Minor, Inc. announced the resignation of its Executive Vice President and Chief Information Officer, Snehashish Sarkar, effective September 26, 2025.
Owens & Minor reported a significant net loss in Q2 2025 due to the classification of its Products & Healthcare Services segment as discontinued operations, while its Patient Direct business showed solid growth.
8-K: Owens & Minor Terminates Rotech Acquisition, Triggers $1 Billion Senior Secured Note Redemption
Owens & Minor, Inc. announced the mutual termination of its merger agreement to acquire Rotech Healthcare Holdings Inc., leading to the mandatory redemption of $1 billion in 10.000% Senior Secured Notes.
Owens & Minor, Inc. announced the mutual termination of its previously planned acquisition of Rotech Healthcare Holdings Inc., incurring an $80 million termination fee and committing to redeem $1 billion in notes issued for the deal.
Owens & Minor held its 2025 Annual Meeting of Shareholders on May 15, 2025, where shareholders voted on the election of directors, ratification of the company's independent auditor, and executive compensation.
8-K: Owens & Minor Reports Mixed Q1 2025 Results; Reaffirms Full-Year Guidance Amid Strategic Review
Owens & Minor announced its Q1 2025 financial results, showing slight revenue growth and reaffirmed its 2025 financial guidance, while continuing to explore the sale of its Products & Healthcare Services segment.
Owens & Minor successfully closes a $1 billion notes offering to fund its acquisition of Rotech Healthcare Holdings Inc.
Owens & Minor has announced the upsize and pricing of a $1 billion senior secured notes offering to finance its acquisition of Rotech Healthcare Holdings Inc.
Owens & Minor announces a private offering of $600 million in senior secured notes to finance its acquisition of Rotech Healthcare Holdings Inc.
Owens & Minor announces a definitive agreement to acquire Rotech Healthcare Holdings, aiming to strengthen its position in the high-growth home healthcare market.
Owens & Minor is exploring the sale of its Products & Healthcare Services segment while reporting a significant debt reduction and projecting double-digit growth in adjusted EBITDA and EPS for 2025.
Owens & Minor released preliminary financial results for the fourth quarter and full year 2024, alongside announcing the commencement of financing activities for the acquisition of Rotech Healthcare Holdings.
Owens & Minor has amended its Executive Deferred Compensation and Retirement Plan, effective January 1, 2025, giving the company more discretion over employer contributions.